These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18971121)

  • 1. Androgens and prostate cancer risk.
    Wirén S; Stattin P
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):601-13. PubMed ID: 18971121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of finasteride on risk of prostate cancer: how little we really know.
    Rubin MA; Kantoff PW
    J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB; Parekh DJ
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer prevention and finasteride.
    D'Amico AV; Barry MJ
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The PCPT trial].
    Hamdy FC; Rouprêt M
    Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
    Goetzl MA; Holzbeierlein JM
    Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
    Mellon JK
    Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.
    Canby-Hagino E; Hernandez J; Brand TC; Thompson I
    Eur Urol; 2007 Jan; 51(1):27-33. PubMed ID: 17030406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hormone-related cancers: prostate cancer.
    Parnes HL; Thompson IM; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):368-77. PubMed ID: 15637399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
    J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
    Villers A
    Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer risk in testosterone-treated men.
    Raynaud JP
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
    Grover S; Lowensteyn I; Hajek D; Trachtenberg J; Coupal L; Marchand S
    J Urol; 2006 Mar; 175(3 Pt 1):934-8; discussion 938. PubMed ID: 16469585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T; Hashimoto Y; Takahashi K
    Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of pivotal studies for prostate cancer risk reduction, past and present.
    Andriole GL
    Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.